Castle (CSTL) Q1 2026 Earnings Report and Guidance Update
Castle Biosciences (CSTL) reported Q1 2026 revenue of $83.7 million, with a 36% year-over-year increase in core test report volumes. The company raised its full-year revenue guidance to $345 million–$350 million. Key drivers included strong growth in DecisionDx-Melanoma and TissueCypher test reports.
Tickers: $CSTL
Topics: financial performance gross margin guidance operating expenses revenue test reports